About Vitro

Vitro Biopharma is a clinical-stage biotechnology company focused on developing Wharton's jelly-derived cell therapies and targeting new treatments for millions of patients with rare and broad indications. Our goal is to become a leader in developing differentiated product candidates in a rapid and efficient manner for the immunology and inflammatory market.

Company Pipeline

Biopharmaceuticals

There are multiple characteristics of umbilical cord MSCs significantly superior to those derived from adipose, bone marrow or placental tissues. Umbilical cord MSCs have superior potency by mitochondrial and immunosuppression measurement and are the youngest adult stem cells, free from age related issues, prior medical conditions and genetics. AlloRx® Stem Cells are ethically sourced and derived from the Wharton’s Jelly of the umbilical cord. Strict screening of the donor's medical & social history is evaluated as well as rigorous testing of the donor's tissue is preformed prior to accepting cords.

Discover Our Science

Developing Differentiated Product Candidates

Derived from the most potent stem cells measured by purity and potency, Wharton’s jelly of the umbilical cord, produced under strict quality control in a cGMP, ISO9001 & ISO13485 Certified environment. Our lead product candidate, AlloRx® has been used internationally to treat a variety of patients with autoimmune and inflammatory diseases, such as COPD, osteoarthritis, multiple sclerosis, Pitt-Hopkin's, Alzheimer’s, and lupus.

Vitro Biopharma has a significant cost advantage within our patent pending, proprietary and scalable manufacturing process.